Recent advancements in COPD treatment have introduced biologic agents such as Dupilumab (anti-IL-4Rα monoclonal antibody), Ensifentrine (a dual PDE3/4 inhibitor), and anti-IL-33 therapies [51–53], which have shown promise in controlling airway inflammation, particularly in patients with type 2 inflammation. This evidence concerns the gene IL4R and inflammatory response.